MCID: PHB003
MIFTS: 32

Phobia, Specific malady

Categories: Mental diseases

Aliases & Classifications for Phobia, Specific

Aliases & Descriptions for Phobia, Specific:

Name: Phobia, Specific 54 13 42 69
Specific Phobia 12 14
Simple Phobia 12

Classifications:



External Ids:

OMIM 54 608251
Disease Ontology 12 DOID:599
ICD10 33 F40.2
MeSH 42 C562465
NCIt 47 C35284
SNOMED-CT 64 192396001 54587008
UMLS 69 C0236801

Summaries for Phobia, Specific

Disease Ontology : 12 A phobic disorder that is characterized by an unreasonable or irrational fear related to exposure to specific objects or situations.

MalaCards based summary : Phobia, Specific, also known as specific phobia, is related to chronic cervicitis and lethal congenital contracture syndrome 1. An important gene associated with Phobia, Specific is PHOBS (Phobia, Specific), and among its related pathways/superpathways are Tyrosine metabolism and Neurotransmitter Clearance In The Synaptic Cleft. The drugs Citalopram and Dopamine have been mentioned in the context of this disorder.

Wikipedia : 71 A specific phobia is any kind of anxiety disorder that amounts to an unreasonable or irrational fear... more...

Description from OMIM: 608251

Related Diseases for Phobia, Specific

Diseases related to Phobia, Specific via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 chronic cervicitis 10.1 FMR1 MAOA
2 lethal congenital contracture syndrome 1 10.1 COMT MAOA
3 renpenning syndrome 10.1 COMT MAOA
4 colorectal adenocarcinoma 10.1 COMT MAOA
5 strongyloidiasis 10.1 COMT MAOA
6 intrahepatic gall duct cancer 10.1 COMT MAOA
7 chronic eosinophilic pneumonia 10.1 COMT MAOA
8 multiple personality disorder 10.0 COMT MAOA
9 cytomegalic congenital adrenal hypoplasia 10.0 COMT MAOA
10 carotid stenosis 10.0 COMT MAOA
11 keratosis 10.0 COMT MAOA
12 cecal benign neoplasm 10.0 COMT MAOA
13 hereditary multiple exostoses 10.0 COMT MAOA
14 lichen disease 10.0 COMT MAOA
15 fechtner syndrome 10.0 COMT MAOA
16 social phobia 10.0
17 basal cell carcinoma 3 10.0 COMT MAOA
18 adult brainstem astrocytoma 10.0 CTU2 MAOA NBAS
19 hepatitis d 9.9 COMT MAOA
20 benign epilepsy with centrotemporal spikes 9.9 COMT MAOA
21 autism spectrum disorder 9.9 COMT FMR1
22 personality disorder 9.9 COMT FMR1 MAOA
23 ellis-van creveld syndrome 9.9 COMT FMR1 MAOA
24 paraphilia disorder 9.8 COMT FMR1 MAOA
25 retinoblastoma 9.8 COMT MAOA
26 anxiety disorder 9.8
27 panic disorder 9.8
28 velocardiofacial syndrome 9.7
29 separation anxiety disorder 9.6
30 hypochondriasis 9.6
31 generalized anxiety disorder 9.6
32 obsessive-compulsive disorder 9.6
33 bipolar disorder 9.6
34 cholestasis-lymphedema syndrome 9.0 COMT CTU2 FMR1 MAOA NBAS PHOBS

Graphical network of the top 20 diseases related to Phobia, Specific:



Diseases related to Phobia, Specific

Symptoms & Phenotypes for Phobia, Specific

Clinical features from OMIM:

608251

Drugs & Therapeutics for Phobia, Specific

Drugs for Phobia, Specific (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 2,Phase 3 59729-33-8 2771
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3 Antidepressive Agents Phase 4,Phase 2,Phase 3
4 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3
5 Antiparkinson Agents Phase 4,Phase 2,Phase 3
6 Autonomic Agents Phase 4,Phase 2,Phase 3
7 Cholinergic Agents Phase 4,Phase 2,Phase 3
8 Cholinergic Antagonists Phase 4,Phase 2,Phase 3
9 Muscarinic Antagonists Phase 4,Phase 2,Phase 3
10 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
11 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
12 Parasympatholytics Phase 4,Phase 2,Phase 3
13 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
14 Psychotropic Drugs Phase 4,Phase 2,Phase 3
15
Serotonin Phase 4,Phase 2,Phase 3 50-67-9 5202
16 Serotonin Agents Phase 4,Phase 2,Phase 3
17 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 3
18 Central Nervous System Stimulants Phase 4
19 Dopamine Agents Phase 4
20 Dopamine Uptake Inhibitors Phase 4
21 Lisdexamfetamine Dimesylate Phase 4
22
Propranolol Approved, Investigational Phase 2, Phase 3 525-66-6 4946
23
Yohimbine Approved, Vet_approved Phase 2, Phase 3 146-48-5 8969
24 Adrenergic Agents Phase 2, Phase 3
25 Adrenergic alpha-Antagonists Phase 2, Phase 3
26 Adrenergic Antagonists Phase 2, Phase 3
27 Adrenergic beta-Antagonists Phase 2, Phase 3
28 Anti-Arrhythmia Agents Phase 2, Phase 3
29 Antihypertensive Agents Phase 2, Phase 3
30 Mydriatics Phase 2, Phase 3
31 Vasodilator Agents Phase 2, Phase 3
32 Pharmaceutical Solutions Phase 3,Phase 2
33 Yohimbe Nutraceutical Phase 2, Phase 3
34
Cycloserine Approved Phase 2,Phase 1 68-41-7 401 6234
35
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
36 Anti-Bacterial Agents Phase 2,Phase 1
37 Antibiotics, Antitubercular Phase 2,Phase 1
38 Anti-Infective Agents Phase 2,Phase 1
39 Antimetabolites Phase 2,Phase 1
40 Antitubercular Agents Phase 2,Phase 1
41 Renal Agents Phase 2,Phase 1
42 Anti-Anxiety Agents Phase 2
43 Antipsychotic Agents Phase 2
44 Central Nervous System Depressants Phase 2
45 Quetiapine Fumarate Phase 2 111974-72-2
46 Tranquilizing Agents Phase 2
47 Antimanic Agents Phase 2
48 Anticonvulsants Phase 2
49 GABA Agents Phase 2
50 Nootropic Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 79)
id Name Status NCT ID Phase
1 Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4
2 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4
3 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Active, not recruiting NCT01863459 Phase 4
4 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
5 Study of Escitalopram in the Treatment of Specific Phobia Completed NCT00121069 Phase 2, Phase 3
6 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370 Phase 2, Phase 3
7 Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Completed NCT02007694 Phase 2, Phase 3
8 Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) Completed NCT02622958 Phase 3
9 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder Recruiting NCT02028247 Phase 3
10 Treatment Study for Rural Latino Youth With Anxiety Unknown status NCT01491880 Phase 1, Phase 2
11 Management and Treatment of Stress-related Disorders (INTERSTRESS) Unknown status NCT01683617 Phase 1, Phase 2
12 Quetiapine in Specific Phobia Completed NCT00872716 Phase 2
13 Treatment for Specific Phobias in Children Completed NCT00051220 Phase 1, Phase 2
14 fMRI Study Examining Effects of D-cycloserine in Specific Phobia Completed NCT00591825 Phase 2
15 D-cycloserine and Treatment of Feeding Disorders Completed NCT01923896 Phase 1, Phase 2
16 Brief Behavioral Treatment for Anxiety in Young Children Completed NCT02051192 Phase 1, Phase 2
17 Influence of Valproic Acid on Extinction-based Therapy in Patients With Fear of Spiders. Recruiting NCT02789813 Phase 2
18 Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training Recruiting NCT02926352 Phase 1, Phase 2
19 Enhancing Exposure Therapy for Snake and Spider Phobias Active, not recruiting NCT02160470 Phase 1, Phase 2
20 The Modular Protocol for Mental Health (MPMH) Not yet recruiting NCT03143634 Phase 1, Phase 2
21 Intervention for Anxiety After Falls Completed NCT01268657 Phase 1
22 Time Intensive CBT for a Specific Phobia of Vomiting Recruiting NCT02920814 Phase 1
23 D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights Unknown status NCT01037101
24 Parent-Augmented Cognitive Behavioral Therapy to Treat Children With Specific Phobias Completed NCT00509951
25 Study of Brain Circuitry in Anxiety Disorders Completed NCT01849432
26 Extinction Generalization in Exposure Therapy Completed NCT03031002
27 Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly Completed NCT02387047
28 Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics Completed NCT01450306
29 Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting Completed NCT02306356
30 In Vivo Versus Augmented Reality Exposure for Small Animal Phobia Completed NCT01361074
31 Internet-delivered Cognitive Behavior Therapy (CBT) for Children Age 8-12 Years With Anxiety Disorders Completed NCT01533402
32 Clinical Management of Anxiety and Access to Health Care Completed NCT02081365
33 Changes in Brain Activity (Functional MRI Study) Before and After Behavioral Therapy of Height Phobia Completed NCT00302978
34 EMDR in Spider Phobia: Work Mechanisms and Treatment Outcome Completed NCT02973919
35 Children and Adolescents With Dental Anxiety - Randomized Controlled Study of Cognitive Behavioral Therapy Completed NCT01798355
36 Use of Virtual Reality in the Treatment of Flying Phobia Completed NCT01442805
37 Cognitive Behavioral Therapy in Panic Disorder Completed NCT00772746
38 CBT vs. ABM vs. for Social Anxiety Completed NCT01909193
39 ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder Completed NCT01963806
40 Variations of Cognitive Behavior Therapy for Social Anxiety Disorder Completed NCT00948974
41 Metacognitive Therapy Versus Cognitive Behavioral Therapy for Mixed Anxiety Disorders: A Randomized Controlled Trial. Completed NCT01889342
42 Prediction of Claustrophobia During MR Imaging Completed NCT01367067
43 The Effect of Psychotherapy on Stress Biochemistry: An RCT of Psychotherapy and Emotional Freedom Techniques (EFT) Completed NCT00641394
44 Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning Completed NCT00062517
45 Retraining Attention to Treat Alcohol Dependence and Social Anxiety Completed NCT01886716
46 Tailored Internet-delivered Cognitive Behaviour Therapy for Symptoms of Depression and Comorbid Problems Completed NCT01181583
47 Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism Completed NCT01563003
48 A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease Completed NCT02302144
49 The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels Completed NCT01385709
50 The Impact of Sex Hormones on One-session Treatment for Spider Phobia in Women Recruiting NCT02622087

Search NIH Clinical Center for Phobia, Specific

Cochrane evidence based reviews: phobia, specific

Genetic Tests for Phobia, Specific

Anatomical Context for Phobia, Specific

Publications for Phobia, Specific

Articles related to Phobia, Specific:

id Title Authors Year
1
Hypochondriasis Differs From Panic Disorder and Social Phobia: Specific Processes Identified Within Patient Groups. ( 27805984 )
2016
2
Biased attention to threat in paediatric anxiety disorders (generalized anxiety disorder, social phobia, specific phobia, separation anxiety disorder) as a function of 'distress' versus 'fear' diagnostic categorization. ( 23591000 )
2014
3
Co-morbid anxiety disorders in bipolar disorder and major depression: familial aggregation and clinical characteristics of co-morbid panic disorder, social phobia, specific phobia and obsessive-compulsive disorder. ( 22099954 )
2012

Variations for Phobia, Specific

Expression for Phobia, Specific

Search GEO for disease gene expression data for Phobia, Specific.

Pathways for Phobia, Specific

GO Terms for Phobia, Specific

Cellular components related to Phobia, Specific according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 dendritic spine GO:0043197 8.62 COMT FMR1

Biological processes related to Phobia, Specific according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neurotransmitter catabolic process GO:0042135 9.16 COMT MAOA
2 catecholamine metabolic process GO:0006584 8.96 COMT MAOA
3 dopamine catabolic process GO:0042420 8.62 COMT MAOA

Sources for Phobia, Specific

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....